Gemcitabine plus docetaxel takes first and second place

Gespeichert in:

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2008

Schlagwörter:	Docetaxel Gemcitabine Objective Response Objective Response Rate Leiomyosarcoma

Anmerkung:	© Adis International Ltd 2008

Übergeordnetes Werk:	Enthalten in: Inpharma weekly - Auckland : ADIS internat., 1975, 1648(2008), 1 vom: Juli, Seite 14-14
Übergeordnetes Werk:	volume:1648 ; year:2008 ; number:1 ; month:07 ; pages:14-14

Links:	Volltext

DOI / URN:	10.2165/00128413-200816480-00044

Katalog-ID:	SPR035329033

Internformat


LEADER	01000caa a22002652 4500
001	SPR035329033
003	DE-627
005	20230519161853.0
007	cr uuu---uuuuu
008	201007s2008 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2165/00128413-200816480-00044 \|2 doi
035			\|a (DE-627)SPR035329033
035			\|a (SPR)00128413-200816480-00044-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Gemcitabine plus docetaxel takes first and second place
264		1	\|c 2008
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Adis International Ltd 2008
650		4	\|a Docetaxel \|7 (dpeaa)DE-He213
650		4	\|a Gemcitabine \|7 (dpeaa)DE-He213
650		4	\|a Objective Response \|7 (dpeaa)DE-He213
650		4	\|a Objective Response Rate \|7 (dpeaa)DE-He213
650		4	\|a Leiomyosarcoma \|7 (dpeaa)DE-He213
773	0	8	\|i Enthalten in \|t Inpharma weekly \|d Auckland : ADIS internat., 1975 \|g 1648(2008), 1 vom: Juli, Seite 14-14 \|w (DE-627)373977859 \|w (DE-600)2127607-9 \|x 2230-6056 \|7 nnns
773	1	8	\|g volume:1648 \|g year:2008 \|g number:1 \|g month:07 \|g pages:14-14
856	4	0	\|u https://dx.doi.org/10.2165/00128413-200816480-00044 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_206
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4305
951			\|a AR
952			\|d 1648 \|j 2008 \|e 1 \|c 07 \|h 14-14

Indexfelder

matchkey_str	article:22306056:2008----::ectbnpudctxlaefrtn
hierarchy_sort_str	2008
publishDate	2008
allfields	10.2165/00128413-200816480-00044 doi (DE-627)SPR035329033 (SPR)00128413-200816480-00044-e DE-627 ger DE-627 rakwb eng Gemcitabine plus docetaxel takes first and second place 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2008 Docetaxel (dpeaa)DE-He213 Gemcitabine (dpeaa)DE-He213 Objective Response (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Leiomyosarcoma (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1648(2008), 1 vom: Juli, Seite 14-14 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1648 year:2008 number:1 month:07 pages:14-14 https://dx.doi.org/10.2165/00128413-200816480-00044 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1648 2008 1 07 14-14
spelling	10.2165/00128413-200816480-00044 doi (DE-627)SPR035329033 (SPR)00128413-200816480-00044-e DE-627 ger DE-627 rakwb eng Gemcitabine plus docetaxel takes first and second place 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2008 Docetaxel (dpeaa)DE-He213 Gemcitabine (dpeaa)DE-He213 Objective Response (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Leiomyosarcoma (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1648(2008), 1 vom: Juli, Seite 14-14 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1648 year:2008 number:1 month:07 pages:14-14 https://dx.doi.org/10.2165/00128413-200816480-00044 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1648 2008 1 07 14-14
allfields_unstemmed	10.2165/00128413-200816480-00044 doi (DE-627)SPR035329033 (SPR)00128413-200816480-00044-e DE-627 ger DE-627 rakwb eng Gemcitabine plus docetaxel takes first and second place 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2008 Docetaxel (dpeaa)DE-He213 Gemcitabine (dpeaa)DE-He213 Objective Response (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Leiomyosarcoma (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1648(2008), 1 vom: Juli, Seite 14-14 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1648 year:2008 number:1 month:07 pages:14-14 https://dx.doi.org/10.2165/00128413-200816480-00044 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1648 2008 1 07 14-14
allfieldsGer	10.2165/00128413-200816480-00044 doi (DE-627)SPR035329033 (SPR)00128413-200816480-00044-e DE-627 ger DE-627 rakwb eng Gemcitabine plus docetaxel takes first and second place 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2008 Docetaxel (dpeaa)DE-He213 Gemcitabine (dpeaa)DE-He213 Objective Response (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Leiomyosarcoma (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1648(2008), 1 vom: Juli, Seite 14-14 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1648 year:2008 number:1 month:07 pages:14-14 https://dx.doi.org/10.2165/00128413-200816480-00044 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1648 2008 1 07 14-14
allfieldsSound	10.2165/00128413-200816480-00044 doi (DE-627)SPR035329033 (SPR)00128413-200816480-00044-e DE-627 ger DE-627 rakwb eng Gemcitabine plus docetaxel takes first and second place 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2008 Docetaxel (dpeaa)DE-He213 Gemcitabine (dpeaa)DE-He213 Objective Response (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Leiomyosarcoma (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1648(2008), 1 vom: Juli, Seite 14-14 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1648 year:2008 number:1 month:07 pages:14-14 https://dx.doi.org/10.2165/00128413-200816480-00044 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1648 2008 1 07 14-14
language	English
source	Enthalten in Inpharma weekly 1648(2008), 1 vom: Juli, Seite 14-14 volume:1648 year:2008 number:1 month:07 pages:14-14
sourceStr	Enthalten in Inpharma weekly 1648(2008), 1 vom: Juli, Seite 14-14 volume:1648 year:2008 number:1 month:07 pages:14-14
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Docetaxel Gemcitabine Objective Response Objective Response Rate Leiomyosarcoma
isfreeaccess_bool	false
container_title	Inpharma weekly
publishDateDaySort_date	2008-07-01T00:00:00Z
hierarchy_top_id	373977859
id	SPR035329033
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035329033</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519161853.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2008 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-200816480-00044</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035329033</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-200816480-00044-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Gemcitabine plus docetaxel takes first and second place</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2008</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 2008</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Docetaxel</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gemcitabine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Objective Response</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Objective Response Rate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Leiomyosarcoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1648(2008), 1 vom: Juli, Seite 14-14</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1648</subfield><subfield code="g">year:2008</subfield><subfield code="g">number:1</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:14-14</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-200816480-00044</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1648</subfield><subfield code="j">2008</subfield><subfield code="e">1</subfield><subfield code="c">07</subfield><subfield code="h">14-14</subfield></datafield></record></collection>
ppnlink_with_tag_str_mv	@@773@@(DE-627)373977859
format	electronic Article
delete_txt_mv	keep
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2230-6056
topic_title	Gemcitabine plus docetaxel takes first and second place Docetaxel (dpeaa)DE-He213 Gemcitabine (dpeaa)DE-He213 Objective Response (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Leiomyosarcoma (dpeaa)DE-He213
topic	misc Docetaxel misc Gemcitabine misc Objective Response misc Objective Response Rate misc Leiomyosarcoma
spellingShingle	misc Docetaxel misc Gemcitabine misc Objective Response misc Objective Response Rate misc Leiomyosarcoma Gemcitabine plus docetaxel takes first and second place
topic_unstemmed	misc Docetaxel misc Gemcitabine misc Objective Response misc Objective Response Rate misc Leiomyosarcoma
topic_browse	misc Docetaxel misc Gemcitabine misc Objective Response misc Objective Response Rate misc Leiomyosarcoma
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Inpharma weekly
hierarchy_parent_id	373977859
hierarchy_top_title	Inpharma weekly
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)373977859 (DE-600)2127607-9
title	Gemcitabine plus docetaxel takes first and second place
ctrlnum	(DE-627)SPR035329033 (SPR)00128413-200816480-00044-e
title_full	Gemcitabine plus docetaxel takes first and second place
journal	Inpharma weekly
journalStr	Inpharma weekly
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2008
contenttype_str_mv	txt
container_start_page	14
container_volume	1648
format_se	Elektronische Aufsätze
doi_str_mv	10.2165/00128413-200816480-00044
title_sort	gemcitabine plus docetaxel takes first and second place
title_auth	Gemcitabine plus docetaxel takes first and second place
abstract	© Adis International Ltd 2008
abstractGer	© Adis International Ltd 2008
abstract_unstemmed	© Adis International Ltd 2008
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305
container_issue	1
title_short	Gemcitabine plus docetaxel takes first and second place
url	https://dx.doi.org/10.2165/00128413-200816480-00044
remote_bool	true
ppnlink	373977859
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.2165/00128413-200816480-00044
up_date	2024-07-03T14:09:18.822Z
_version_	1803567244324634624
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035329033</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519161853.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2008 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-200816480-00044</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035329033</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-200816480-00044-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Gemcitabine plus docetaxel takes first and second place</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2008</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 2008</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Docetaxel</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gemcitabine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Objective Response</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Objective Response Rate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Leiomyosarcoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1648(2008), 1 vom: Juli, Seite 14-14</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1648</subfield><subfield code="g">year:2008</subfield><subfield code="g">number:1</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:14-14</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-200816480-00044</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1648</subfield><subfield code="j">2008</subfield><subfield code="e">1</subfield><subfield code="c">07</subfield><subfield code="h">14-14</subfield></datafield></record></collection>
score	7.399705

Nicht das Richtige dabei?

Schreiben Sie uns!

Gemcitabine plus docetaxel takes first and second place

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?